To evaluate the efficacy of subconjunctival Bevacizumab injection in vascular Pterygium before surgical excision in preventing recurrence comparing with bare sclera technique

no subtitle

  • Abdul Gafoor Ahmed Ophthalmology
  • Sheikh Sajjad
Keywords: no

Abstract

Background: The prevalence of Pterygium in the world is 10.2% with highest prevalence in low altitude regions.  Etiology of Pterygium is not known but Increased incidence of Pterygium is noted in tropics and in equatorial zones 30 degree North and south latitude. Bevacizumab is a full-length humanized monoclonal antibody directed against all biologically active forms of vascular endothelial growth factor (VEGF).  Bevacizumab binds to soluble VEGF and inhibits the binding of VEGF molecules to its receptors on the surface of endothelial cells. It is a non specific VEGF inhibitor with two binding sites per molecule.

Objectives: To evaluate the efficacy of subconjunctival bevacizumab 2.5mg per 0.1ml injection before Pterygium surgery with Bare Sclera technique in preventing postoperative reoccurrence.

Methods: 100 patients with primary vascular pterygium attending the ophthalmology Department of SKIMS Medical College and Hospital Srinagar were enrolled. Patients included were divided into two groups of 50 patients each. Patients in Group A received Bevacizumab 2.5mg/0.1ml and patients in Group B received subconjunctival balanced salt solution 0.1ml.

Results: Majority of patients in both the groups were 30-39 years of age i.e. 16 (32%) in Group A with a mean age of 36.2+8.72 years with youngest patients being 20 years and the oldest 56 years of age. Females outnumber the males with 46 males and 56 females. Left eye was involved in more i.e. 61 than the right eye 39. Majority of patients in Group A i.e. 30 (60%) and Group B 31 (62%) had Grade 2 pterygium following by Grade 3 pterygium in 17 (34%) in Group A and 15 (30%) in Group B. Only 3 (6%) and 4 (8%) in Group A and Group B had Grade 1 pterygium. Mean preoperative intraocular pressure (mmHg) observed in Group A was 15.06mmHg and in Group B it was 15.34mmHg with a statistically insignificant difference (p 0.241). In Group A, 27 (54%) and in Group B, 29 (58%) patients had best corrected visual acuity of 6/6, followed by BCVA of 6/9 in 19 (38%) and 16 (32%) in Group A and Group B. Best corrected visual acuity of 6/12 was seen in 4 (8%) patients and 5 (10%) in Group A and Group B respectively .Recurrence of pterygium was observed at 6 weeks and 6 months ,at 6 weeks it was seen that  3 (6 %) patients in group A and 11 (22 %) in group B had recurrent pterygium (P value less than 0.05 % statistically significant difference) and at six months follow up it was seen that 4( 8 %) patients in group A and 13( 26 % ) in group B had recurrent pterygium ( P value less than 0.05 %, statistically significant difference ). Mean postoperative intraocular pressure in Group A was 15.36+1.04mmHg and in Group B it was 15.58+1.12mmHg. Only postoperative complication encountered was Granuloma in 1 (2%) in Group A and 2 (4%) patients in Group B.

Conclusion: Subconjunctival injection of bevacizumab at a dose of 2.5mg (0.1ml) one week before surgery of pterygium is safe and effective in terms of recurrence and the complication rate for primary or recurrent pterygium treatment.  No adverse effects were reported among the treated patients, confirming the relative safety of this drug and dose.

Downloads

Download data is not yet available.
Published
2021-05-01
How to Cite
1.
Ahmed A, Sajjad S. To evaluate the efficacy of subconjunctival Bevacizumab injection in vascular Pterygium before surgical excision in preventing recurrence comparing with bare sclera technique. jms [Internet]. 2021May1 [cited 2026Nov.18];24(Suppl 1). Available from: https://old.jmsskims.org/index.php/jms/article/view/922